Target intelligence / Profile preview

Lipoprotein particle (LP)

Target
LP
Molecular classification
Lipoprotein, Macromolecular complex, Lipid-protein assembly
01

Overview

Lipoprotein particles are complex macromolecular assemblies composed of a hydrophobic core of triglycerides and cholesterol esters surrounded by a hydrophilic shell of phospholipids, free cholesterol, and specialized proteins called apolipoproteins. Their primary biological function is the transport of water-insoluble lipids through the aqueous environment of the bloodstream to various tissues for energy utilization, storage, or membrane synthesis. These particles are classified by their density and composition into several classes, including chylomicrons, VLDL, LDL, and HDL, each playing distinct roles in lipid metabolism. In clinical medicine, these particles are central targets for therapeutic intervention because elevated levels of pro-atherogenic particles (like LDL) are directly linked to the development of atherosclerosis and coronary heart disease. Pharmacological strategies often focus on reducing the circulating concentration of these particles by inhibiting their synthesis, promoting their clearance via hepatic receptors, or physically sequestering their precursors in the digestive tract.

Other names
Lipid particlesPlasma lipoproteinsLipoprotein complexesChylomicronsVery-low-density lipoprotein (VLDL)Low-density lipoprotein (LDL)High-density lipoprotein (HDL)Intermediate-density lipoprotein (IDL)
02

Mechanism of action

Sequestration of bile acids to increase LDL clearance, inhibition of hepatic synthesis, enhancement of receptor-mediated endocytosis, and modulation of lipid exchange between particles.

03

Biological functions

Lipid transportCholesterol homeostasisTriglyceride metabolismFat-soluble vitamin transportSignal transduction
04

Disease associations

AtherosclerosisHyperlipidemiaCardiovascular diseaseMetabolic syndromeHypercholesterolemiaNonalcoholic fatty liver disease (NAFLD)
05

Safety considerations

Gastrointestinal distressMalabsorption of fat-soluble vitaminsMyopathy (when combined with other lipid-modifying agents)Increased risk of cholelithiasis
06

Interacting drugs

Colesevelam

8 more in the full profile.

07

Biomarkers

LDL-C (Low-density lipoprotein cholesterol)HDL-C (High-density lipoprotein cholesterol)Apolipoprotein B (ApoB)Apolipoprotein A1 (ApoA1)Triglyceride levels

Beyond the preview

Go deeper on Lipoprotein particle (LP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipoprotein particle (LP).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call